Haemonetics Corporation(NYSE:HAE) announced the earnings results for Fiscal Year 2017 and Q3. The results came in during Pre-Market on Feb 6, 2017. Company reported revenue of $227.841M. Analysts estimated a revenue of $219.710M. The revenues were 3.7% above the estimates. Earnings per share were $0.43. The reported EPS was above estimates by 7.5%. Analysts had estimated an EPS of $0.4.
Haemonetics Corporation (HAE) shares turned negative on Tuesdays trading session with the shares closing down -0.85 points or -2.24% at a volume of 15,02,089. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $38.47. The peak price level was also seen at $38.47 while the days lowest was $36.67. Finally the shares closed at $37.15. The 52-week high of the shares is $41.65 while the 52-week low is $25.98. According to the latest information available, the market cap of the company is $1,932 M.
Several Insider Transactions has been reported to the SEC. On Dec 14, 2016, Ronald G Gelbman (director) sold 5,683 shares at $40.30 per share price.Also, On Aug 19, 2016, Ronald Merriman (director) sold 4,337 shares at $35.15 per share price.On Aug 16, 2016, Susan Bartlett Foote (director) sold 14,685 shares at $35.34 per share price, according to the Form-4 filing with the securities and exchange commission.
Haemonetics Corporation is a healthcare company which provides blood management solutions to its customers. The Company’s portfolio of integrated devices information management and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma Blood Center Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma North America Blood Center and Hospital Europe Asia Pacific and Japan.